Shawnalyn W Sunagawa, Carly Cloud Floyd, Sara H Bares, Anthony T. Podany, Kimberly K. Scarsi, Timothy Mykris, Lee C. Winchester, Jennifer O’Neill, Maureen Kubat, Christine Tran, Jennifer M Davis, Jeremy W Snyder, Joshua P Havens
We present pharmacokinetic data on long-acting cabotegravir/rilpivirine (LA CAB/RPV) from two patients during their second and third trimesters. Monthly LA CAB/RPV dosing maintained concentrations above the proposed efficacy thresholds while bimonthly dosing resulted in subtherapeutic RPV concentrations. This highlights the potential of monthly LA CAB/RPV dosing in pregnancy.